Advanced searches left 3/3

Metastatic Malignant Melanoma - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 02 November 2021

* If you want to update the article please login/register

Phase II Randomized, Parallel-Group Trial on PTK-ZK With or Without DTIC in Patients With Non-resectable Metastatic Malignant Melanoma

Patients in Arm B additionally obtain intravenous DTIC 850mg/m ² on day 1 of each cycle. After informed authorization is offered by the patient a biopsy from a transition should be taken prior to the first intake of research study drug and at the end of cycle 2 to define markers of angiogenesis and MVD.

Source link: https://clinicaltrials.gov/ct2/show/NCT00615160

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions